The Peripheral Amyloid-β Nexus: Connecting Alzheimer's Disease with Atherosclerosis through Shared Pathophysiological Mechanisms

被引：0

作者：

Khowdiary, Manal M. ^{[1
]}

Al-kuraishy, Hayder M. ^{[2
]}

Al-Gareeb, Ali I. ^{[3
]}

Albuhadily, Ali K. ^{[2
]}

Elhenawy, Ahmed A. ^{[4
,5
]}

Rashwan, Eman K. ^{[6
]}

Alexiou, Athanasios ^{[7
,8
]}

Papadakis, Marios ^{[9
]}

Abo-El Fetoh, Mohammed E. ^{[10
]}

Batiha, Gaber El-Saber ^{[11
]}

机构：

[1] Umm Al Qura Univ, Fac Sci Appl, Dept Chem, Lieth Coll, Mecca, Saudi Arabia

[2] Mustansiriyah Univ, Coll Med, Dept Clin Pharmacol & Med, Baghdad, Iraq

[3] Jabir ibn Hayyan Med Univ, POB 13, Kufa, Kufa, Iraq

[4] Al Azhar Univ, Fac Sci, Chem Dept, Cairo 11884, Egypt

[5] AlBaha Univ, Fac Sci, Chem Dept, Al Bahah 65731, Saudi Arabia

[6] Jouf Univ, Coll Med, Dept Physiol, Akaka, Saudi Arabia

[7] Funogen, Dept Res & Dev, Athens 11741, Greece

[8] Chandigarh Univ, Univ Ctr Res & Dev, Chandigarh Ludhiana Highway, Mohali, Punjab, India

[9] Univ Witten Herdecke, Univ Hosp, Heusnerstre 40, D-42283 Wuppertal, Germany

[10] Egyptian Russian Univ, Fac Pharm, Pharmacol & Toxicol Dept, Badr City 11829, Cairo, Egypt

[11] Damanhour Univ, Fac Vet Med, Dept Pharmacol & Therapeut, Damanhour 22511, AlBeheira, Egypt

来源：

NEUROMOLECULAR MEDICINE | 2025年 / 27卷 / 01期

关键词：

Alzheimer's disease; Atherosclerosis; Amyloid-beta (A beta); Vascular dysfunction; Neuroinflammation; Oxidative stress; Insulin resistance; A beta clearance pathways; PRECURSOR PROTEIN; BACE1; ACTIVITY; A-BETA; RISK; INFLAMMATION; DYSFUNCTION; DEMENTIA; TAU; NEUROPATHOLOGY; ABNORMALITIES;

D O I：

10.1007/s12017-025-08836-2

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Alzheimer's disease (AD) and atherosclerosis (AS) are two chronic diseases with seemingly distinct pathologies. However, emerging research points to a bidirectional relationship driven by common mechanisms, such as inflammation, oxidative stress, and dysregulation of Amyloid-Beta (A beta). This review focuses on the role of A beta as a critical molecular link between AD and AS, emphasizing its contribution to neuronal impairment and vascular damage. Specifically, peripheral A beta produced in the pancreas and skeletal muscle tissues exacerbates AS by promoting endothelial dysfunction and insulin resistance (IR). Furthermore, AS accelerates AD progression by impairing cerebral blood flow and inducing chronic hypoxia, causing A beta accumulation. This review critically evaluates recent findings, highlighting inconsistencies in clinical studies and suggesting future research directions. Understanding the bidirectional influence of AD and AS could pave the way for novel therapeutic approaches targeting shared molecular pathways, particularly emphasizing A beta clearance and inflammation.

引用

页数：13

共 106 条

[31] Garcia-Mejia K.A., Custodio-Chable S.J., Vazquez-Franco J.E., Reyes-Maldonado E., Lezama R.A., Beta-Amyloid Orchestrates Factor XII and platelet activation leading to endothelial dysfunction and abnormal fibrinolysis in alzheimer disease, Alzheimer Disease and Associated Disorders, 35, 1, pp. 91-97, (2021)
[32] Gergiopoulos G., Mavroeidis I., Sopova K., Sacshe M., Delialis D., Mareti A., Et al., Amyloid beta 1–40 and its upstream regulatory pathway bace1-as long noncoding RNA/bace1 are associated with presence and severity of human atherosclerotic disease, Journal of Hypertension, 37, (2019)
[33] Gronewold J., Klafki H.W., Baldelli E., Kaltwasser B., Seidel U.K., Todica O., Et al., Factors responsible for plasma beta-amyloid accumulation in chronic kidney disease, Molecular Neurobiology, 53, 5, pp. 3136-3145, (2016)
[34] Guo Z., Peng X., Li H.Y., Wang Y., Qian Y., Wang Z., Et al., Evaluation of peripheral immune dysregulation in Alzheimer's disease and vascular dementia, Journal of Alzheimer's Disease, 71, 4, pp. 1175-1186, (2019)
[35] Guo Y., Wang Q., Chen S., Xu C., Functions of amyloid precursor protein in metabolic diseases, Metabolism, 115, (2021)
[36] Gupta A., Iadecola C., Impaired Aβ clearance: a potential link between atherosclerosis and Alzheimer's disease, Review. Frontiers in Aging Neuroscience, (2015)
[37] Gustavsson A.M., van Westen D., Stomrud E., Engstrom G., Nagga K., Hansson O., Midlife atherosclerosis and development of Alzheimer or vascular dementia, Annals of Neurology, 87, 1, pp. 52-62, (2020)
[38] He J., Gao Y., Yang C., Guo Y., Liu L., Lu S., Et al., Navigating the landscape: Prospects and hurdles in targeting vascular smooth muscle cells for atherosclerosis diagnosis and therapy, Journal of Controlled Release, 366, pp. 261-281, (2024)
[39] Hernandez L., Ward L.J., Arefin S., Ebert T., Laucyte-Cibulskiene A., Collaborators G.-F., Et al., Blood-brain barrier and gut barrier dysfunction in chronic kidney disease with a focus on circulating biomarkers and tight junction proteins, Science and Reports, 12, 1, (2022)
[40] Herrera-Rivero M., Santarelli F., Brosseron F., Kummer M.P., Heneka M.T., Dysregulation of TLR5 and TAM ligands in the Alzheimer's brain as contributors to disease progression, Molecular Neurobiology, 56, 9, pp. 6539-6550, (2019)

← 1 2 3 4 5 6 7 8 9 10 →